Single User License
INR 102255
Site License
INR 204510
Corporate User License
INR 306765

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015

Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Isis Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Isis Pharmaceuticals, Inc. Snapshot 7

Isis Pharmaceuticals, Inc. Overview 7

Key Information 7

Key Facts 7

Isis Pharmaceuticals, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Isis Pharmaceuticals, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Isis Pharmaceuticals, Inc.-Pipeline Products Glance 17

Isis Pharmaceuticals, Inc.-Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Isis Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Isis Pharmaceuticals, Inc.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Isis Pharmaceuticals, Inc.-Drug Profiles 22

ISIS-TTRRx 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

nusinersen 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ISIS-CRPRx 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

ISIS-EIF4ERx 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ISIS-FXIRx 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ISIS-GCCRRx 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

ISIS-GCGRRx 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ISIS-PTP1BRx 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

ISIS-DMPK-2.5 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

ISIS-APOALRx 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ISIS-FGFR4Rx 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ISIS-HBVRx 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ISIS-PKKRx 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ISIS-AATRx 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ISIS-AGTLRx 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ISIS-APOCIIILRx 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

ISIS-BIIB3Rx 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ISIS-DGAT2Rx 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ISIS-FVIIRx 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ISIS-GHRLRx 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ISIS-HTTRx 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

ISISGSK-4L 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ISISGSK-6L 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ISISRHO-2.5Rx 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Antisense Oligonucleotide 1 for Neurological and Neuromuscular Disorders 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Antisense Oligonucleotide 2 for Neurological and Neuromuscular Disorders 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Isis Pharmaceuticals, Inc.-Pipeline Analysis 53

Isis Pharmaceuticals, Inc.-Pipeline Products by Target 53

Isis Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 55

Isis Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 57

Isis Pharmaceuticals, Inc.-Recent Pipeline Updates 59

Isis Pharmaceuticals, Inc.-Dormant Projects 71

Isis Pharmaceuticals, Inc.-Discontinued Pipeline Products 72

Discontinued Pipeline Product Profiles 72

ISIS-104838 72

ISIS-113715 72

ISIS-14803 72

ISIS-2503 72

ISIS-5132 73

ISIS-CRPRx 73

ISIS-EIF4ERx 73

Isis Pharmaceuticals, Inc.-Company Statement 74

Isis Pharmaceuticals, Inc.-Locations And Subsidiaries 76

Head Office 76

Other Locations & Subsidiaries 76

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

Isis Pharmaceuticals, Inc., Key Information 7

Isis Pharmaceuticals, Inc., Key Facts 7

Isis Pharmaceuticals, Inc.-Pipeline by Indication, 2015 9

Isis Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Isis Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Isis Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Isis Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 14

Isis Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 15

Isis Pharmaceuticals, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Isis Pharmaceuticals, Inc.-Phase III, 2015 17

Isis Pharmaceuticals, Inc.-Phase II, 2015 18

Isis Pharmaceuticals, Inc.-Phase I, 2015 19

Isis Pharmaceuticals, Inc.-Preclinical, 2015 20

Isis Pharmaceuticals, Inc.-Discovery, 2015 21

Isis Pharmaceuticals, Inc.-Pipeline by Target, 2015 54

Isis Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 55

Isis Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 58

Isis Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 59

Isis Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 71

Isis Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 72

Isis Pharmaceuticals, Inc., Subsidiaries 76

List of Figures

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 9

Isis Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Isis Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Isis Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Isis Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 15

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 53

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 55

Isis Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 56

Isis Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Isis Pharmaceuticals, Inc.; Isis Pharmaceuticals, Inc. - Key Therapeutics; Isis Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Isis Pharmaceuticals, Inc. - News; Isis Pharmaceuticals, Inc. - Latest Updates; Isis Pharmaceuticals, Inc. - Pipeline; Isis Pharmaceuticals, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com